Cargando…
The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort
BACKGROUND: Serum fibroblast growth factor 23 (FGF-23) levels are markedly elevated in haemodialysis patients and have been linked to mortality outcomes. Small studies in health and chronic kidney disease, have demonstrated marked intra- and inter-individual variability in measured FGF-23 levels, an...
Autores principales: | Damasiewicz, Matthew J., Lu, Zhong X., Kerr, Peter G., Polkinghorne, Kevan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236962/ https://www.ncbi.nlm.nih.gov/pubmed/30428848 http://dx.doi.org/10.1186/s12882-018-1127-7 |
Ejemplares similares
-
A pilot study comparing the efficiency of a novel asymmetric cellulose triacetate (ATA) dialyser membrane (Solacea‐190H) to a standard high flux polysulfone dialyser membrane (FX‐80) in the setting of extended hours haemodialysis
por: Kameshwar, Kamya, et al.
Publicado: (2022) -
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial
por: Roberts, Matthew A., et al.
Publicado: (2016) -
Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c‐terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients
por: Yamashita, Kazuomi, et al.
Publicado: (2017) -
Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis
por: Tong, Allison, et al.
Publicado: (2015) -
25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study
por: Damasiewicz, Matthew J, et al.
Publicado: (2012)